Tricida upgraded by JP Morgan with a new price target
$TCDA
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2022 | $25.00 | Buy | Goldman |
| 11/16/2021 | $7.00 | Underweight → Neutral | JP Morgan |